Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy

Autor:	Bernard F. Hearon, Kyle N. Redelman, Georges C. Elhomsy, Dennis F. Moore, Jr.
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	immune checkpoint inhibitor immune-related endocrinopathy malignant pleural mesothelioma regression programmed cell death ligand 1 expression pembrolizumab monotherapy therapeutic biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Case Reports in Oncology, Vol 13, Iss 3, Pp 1483-1489 (2020)
Druh dokumentu:	article
ISSN:	1662-6575
DOI:	10.1159/000512013
Popis:	The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1 negative, experienced a prompt and exceptionally favorable response to pembrolizumab monotherapy. After cessation of treatment due to immune-related endocrinopathies, complete metabolic response on interim PET/CT scan was achieved. Two years after initial diagnosis, unifocal tumor reactivation was addressed with successful pembrolizumab monotherapy rechallenge. Immunotherapy, typically not used as frontline treatment for malignant pleural mesothelioma, may provide an effective and durable response for some patients. Based on this single case study, epithelioid type tumors with strongly positive PD-L1 and BAP1-negative immunohistochemical markers may be well suited for treatment with immune checkpoint inhibitors such as pembrolizumab.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/a4ac580114ce420289dd1bf82587a67a Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.